ArticleScientific reports2016
Human cellular CYBA UTR sequences increase mRNA translation without affecting the half-life of recombinant RNA transcripts.
Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 44 citations in OpenAlex.
- Article
- mRNA therapy improves the composition and motility in CCDC40-deficient cilia in vitro and in vivo.American journal of respiratory cell and molecular biology · 2026Article
- mRNA therapeutics: Transforming medicine through innovation in design, delivery, and disease treatment.Molecular therapy. Nucleic acids · 2025Review
- Engineering bone tissue with mRNA: from molecular design and delivery to clinical applications.Materials today (Kidlington, England) · 2025Article
- Targeting and tracking mRNA lipid nanoparticles at the particle, transcript and protein level.Nature biomedical engineering · 2025Review
- Implementing BMP-7 Chemically Modified RNA for Bone Regeneration with 3D Printable Hyaluronic Acid-Collagen Granular Gels.Advanced healthcare materials · 2025Article
- UTR-Insight: integrating deep learning for efficient 5' UTR discovery and design.BMC genomics · 2025Article
- Optimization of the 5' untranslated region of mRNA vaccines.Scientific reports · 2024Article
- A novel deep generative model for mRNA vaccine development: Designing 5' UTRs withActa pharmaceutica Sinica. B · 2024Article
- Messenger RNA Therapy for Female Reproductive Health.Molecular pharmaceutics · 2024Review
- mRNA-based therapeutics: powerful and versatile tools to combat diseases.Signal transduction and targeted therapy · 2022Review
- Combinatorial optimization of mRNA structure, stability, and translation for RNA-based therapeutics.Nature communications · 2022Article
- Efficient healing of large osseous segmental defects using optimized chemically modified messenger RNA encoding BMP-2.Science advances · 2022Article
- mRNA - A game changer in regenerative medicine, cell-based therapy and reprogramming strategies.Advanced drug delivery reviews · 2021Review
- Combinatorial optimization of mRNA structure, stability, and translation for RNA-based therapeutics.bioRxiv : the preprint server for biology · 2021Article
- The Ins and Outs of Messenger RNA Electroporation for Physical Gene Delivery in Immune Cell-Based Therapy.Pharmaceutics · 2021Review
- Leveraging mRNA Sequences and Nanoparticles to Deliver SARS-CoV-2 Antigens In Vivo.Advanced materials (Deerfield Beach, Fla.) · 2020Article
- Progress toward Eukaryotic Semisynthetic Organisms: Translation of Unnatural Codons.Journal of the American Chemical Society · 2019Article
- Delivery of mRNA Therapeutics for the Treatment of Hepatic Diseases.Molecular therapy : the journal of the American Society of Gene Therapy · 2019Review
- Segmented poly(A) tails significantly reduce recombination of plasmid DNA without affecting mRNA translation efficiency or half-life.RNA (New York, N.Y.) · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Modified nucleotide chemistries that increase the half-life (T
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.